Search
Fusarium oxysporum
go.drugbank.com/drugs/DB10806ApprovedFusarium oxysporum allergenic extract is used in allergenic testing.
Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureDengue virus serotype 1
go.drugbank.com/drugs/DB22664ApprovedDengue virus serotype 1 is a serotype of _Orthoflavivirus denguei_ known to cause dengue fever. … [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]
Synonyms: Dengue virus type 1, Dengue virus serotype 1Nilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigationalA Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec … Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML).
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: TASIGNA® 150 MG CAPSULASSpectinomycin
go.drugbank.com/drugs/DB00919ApprovedVet approvedWithdrawnIt is active against gram-negative bacteria and used for the treatment of gonorrhea.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 3-RingProducts: Spectro 5% w/v Oral Solution, TROBICIN FOR INJECTION 2 g/vialPanobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. … Panobinostat is marketed by Novartis under the brand name Farydak.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-Thiotepa
go.drugbank.com/drugs/DB04572ApprovedInvestigationalIt is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. … N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years.
Synonyms: N,N′,N′′-tri-1,2-ethanediyl-, Phosphorothioic triamide, N,N′,N′′-tri-1,2-ethanediyl-Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesOsilodrostat
go.drugbank.com/drugs/DB11837ApprovedInvestigationalCushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. … Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol.
Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesMirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigationalMirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. … Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: MYRBETRIC® 50 MG TABLETAS DE LIBERACION PROLONGADA, MYRBETRIC® 25 MG TABLETAS DE LIBERACION PROLONGADACX-051869
go.drugbank.com/drugs/DB31656ApprovedCX-051869 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage LP.8.1. … It is the active ingredient of the 2025-2026 formulation of Moderna's Spikevax vaccine.[L40074]
Vilazodone
go.drugbank.com/drugs/DB06684ApprovedInvestigationalVilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. … Vilazodone may also be associated with less sexual dysfunction and weight gain[A6947]. Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 Substrates